Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Still a Buy?

Posted by Amy Steele on Nov 11th, 2026

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report)’s share price gapped up before the market opened on Monday. The stock had previously closed at $21.58, but opened at $23.3499. Chugai Pharmaceutical shares last traded at $22.6905, with a volume of 20,992 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CHGCY. UBS Group downgraded Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Nomura raised Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Check Out Our Latest Report on CHGCY

Chugai Pharmaceutical Stock Down 1.7%

The stock has a market capitalization of $74.16 billion, a price-to-earnings ratio of 23.47 and a beta of 0.60. The company’s fifty day simple moving average is $20.77 and its 200 day simple moving average is $24.37.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last announced its earnings results on Tuesday, October 27th. The company reported $0.27 EPS for the quarter. The business had revenue of $2.54 billion during the quarter, compared to the consensus estimate of $2.29 billion. Chugai Pharmaceutical had a net margin of 35.63% and a return on equity of 24.91%. As a group, analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 1.00 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

(Get Free Report)

Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its work focuses on areas including oncology, immunology, hematology and neuroscience, and its portfolio includes biologic and antibody-based medicines as well as other pharmaceutical products. The company was established in Japan in 1925 and is headquartered in Tokyo. Since 2002, Chugai has been part of the Roche Group through a strategic alliance, while continuing to operate as a Japan-based pharmaceutical company.